-
公开(公告)号：US20190008862A1
公开(公告)日：2019-01-10
申请号：US16127921
申请日：2018-09-11
IPC分类号： A61K31/501 , A61K31/7048 , A61K31/55 , A61K31/444 , A61K31/4427 , A61K31/4412 , A61K31/4166 , A61K31/40 , A61K31/341 , A61P9/04
摘要： A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
-
公开(公告)号：US11413285B2
公开(公告)日：2022-08-16
申请号：US16127921
申请日：2018-09-11
IPC分类号： A61K31/501 , A61P9/04 , A61K31/4166 , A61K31/4412 , A61K31/4427 , A61K31/444 , A61K31/341 , A61K31/40 , A61K31/55 , A61K31/7048
摘要： A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
-
3.发明授权公开(公告)号：US10537588B2
公开(公告)日：2020-01-21
申请号：US15865339
申请日：2018-01-09
发明人： Juergen Daemmgen , Olaf Joens , Rainer Kleemann
IPC分类号： A61K31/50 , A61K31/501 , A61K31/44 , A61K31/444 , A61K31/4166 , A61P9/04 , A61P9/08 , A61K31/7048 , A61K31/4412 , A61K31/4427 , A61K31/341 , A61K31/40 , A61K45/06
摘要： A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
-
公开(公告)号：US10537570B2
公开(公告)日：2020-01-21
申请号：US15477188
申请日：2017-04-03
发明人： Christoph Schummer , Olaf Joens
IPC分类号： A61K31/501 , A61K31/55 , A61K31/635 , A61K31/50 , A61P9/04 , A61K9/20
摘要： The invention relates to pimobendan for use in a method of reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), and/or delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), wherein the patient is preferably a mammal, more preferably a human, a dog, a cat or a horse, and most preferably a dog.
-
公开(公告)号：US12011441B2
公开(公告)日：2024-06-18
申请号：US16131499
申请日：2018-09-14
IPC分类号： A61K31/501 , A61K31/50 , A61K31/55 , A61K31/635 , A61P9/04 , A61K9/20
CPC分类号： A61K31/501 , A61K31/50 , A61K31/55 , A61K31/635 , A61P9/04 , A61K9/20 , A61K2300/00 , A61K31/55 , A61K2300/00 , A61K31/501 , A61K2300/00 , A61K31/635 , A61K2300/00
摘要： Pimobendan is used for reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), and/or delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), wherein the patient is preferably a mammal, more preferably a human, a dog, a cat or a horse, and most preferably a dog.
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
